Research and Markets (http://www.researchandmarkets.com/research/c84a4e/forecast_insight) has announced the addition of the “Forecast Insight: Parkinson’s Disease – Market Upgrade following Evidence of Disease Slowing with Azilect” report to their offering.
Stimulated by evidence of disease slowing with Teva/Lundbecks Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson’s disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (2007-2013), peaking at $3.1 billion in 2013.
Scope
— This report gives a strategic analysis of the likely impact that recent events will have on the future Parkinson’s disease market
— Includes Parkinson’s disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
— Provides a global market snapshot by including Parkinson’s disease-specific sales analysis for leading brands outside the seven major markets
— Key conclusions are supported by key opinion leader comment
Highlights of this title
Datamonitor has upgraded its forecasts of Teva/Lundbecks Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson’s disease drug at this time.
GlaxoSmithKlines Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheims Mirapex (pramipexole).
Datamonitor has downgraded its sales forecasts of UCBs Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCBs misfortune.
Key reasons to purchase this title
— Understand the impact of recent and anticipated events on the Parkinson’s disease market during the forecast period 2008 to 2017
— Quantify the current size of the seven major markets and the trends in the rest of the world
— Assess the impact of events, such as patent expiries and new product launches, on the Parkinson’s disease-specific sales of key brands
Key Topics Covered: EXECUTIVE SUMMARY - Strategic scoping and focus - Insight into the disease market - Contributing experts - Related reports MARKET DEFINITION AND OVERVIEW - Market definition for this report - Current seven major market assessment - Indication break-down for ATC class N4A-Anti-Parkinson Drugs - Rapidly developing restless legs syndrome market in the US - Parkinsons disease-specific current market value - The 5EU is the largest market for Parkinson disease and is growing at the quickest rate - Individual 5EU markets show significant growth - Dominance of the 5EU market is driven by demographics - Demographics account for the differences among markets - Price premium in the US is less evident in Parkinsons disease - Key events impacting the Parkinsons disease market - Rest of World snapshot - Rest of the world (ROW) revenue similar to that generated by the US - Growth observed in the rest of the world (ROW) over the last 4 years - Leading brand sales in the rest of the world (ROW) - Potential for growth in the BRIC (Brazil, Russia, India and China) countries - Total elderly population in BRIC is larger than in the seven major markets - Growth of the Parkinsons disease market in BRIC countries lags behind total drug spend - Future seven major market assessment - Azilect and dopamine agonist reformulations drive future growth - Key events impacting Datamonitors Parkinsons disease market forecast - Shifting drug class dynamics - EU market continues to lead Parkinsons disease sales - Sales forecasts revised upwards - Parkinsons disease market sales forecast overview BRAND DYNAMICS - Overview of competitive landscape - Current market landscape - Future market landscape - Key drugs in late-stage development for Parkinsons disease - Leading marketed brands - Mirapex (pramipexole) and pramipexole extended-release (Boehringer Ingelheim) - Competition from Requip XL threatens Mirapex - Boehringer Ingelheim developing pramipexole extended-release to combat competition - Forecast for the pramipexole franchise - Pramipexole extended-release clinical trial program - Mirapex instant-release patent situation - Requip IR and XL (ropinirole instant-release and extended-release, GlaxoSmithKline) - Requip XL development and launch - Requip IR is the second most successful dopamine agonist brand - Timely life-cycle management strategy - Requip IR and XL forecasts - Azilect (rasagiline, Teva and Lundbeck) - Evidence of disease slowing impacts forecasts - Disease slowing proven with ADAGIO trial - Switching from selegiline and new patients drives growth - Azilect forecast - Azilect patent situation - uncertainty expressed in scenario forecasts - Stalevo (entacapone/carbidopa/levodopa) and Comtan (entacapone) (Novartis and Orion) - Drug overview- Comtan - Drug overview- Stalevo - Forecast for Comtan and Stalevo - Patent situation for Comtan and Stalevo - Neupro (rotigotine CDS, UCB) - Uptake was strong in the launched markets throughout 2006 and 2007 - Batch formulation problems - GlaxoSmithKline set to benefit from UCBs misfortune - Neupro forecast - Promising pipeline drugs - Safinamide (NW-1015, Merck-Serono and Newron, Phase III) - Differentiation from established products difficult - Impact of developments over the last 12 months on safinamides commercial potential - Ongoing clinical program - Safinamide forecast - SLV-308 (pardoprunox, Solvay, Phase III) - SLV-308 forecast - Pimavanserin (ACP-103, Acadia, Phase III) - Competing with off-label antipsychotic use - Forecast - Lisuride formulations (Nenad, Lisuride SubQ, Axxonis Pharma and Prestwick Pharmaceuticals, pre-registration) - Lisuride forecasts - Datamonitor comment - safety is the big concern - Nenad (Lisuride transdermal patch) - pre-registration in EU - Lisuride Sub Q (lisuride subcutaneous infusion) - pre-registration in EU - Apomorphine formulations (Aspirair (Vectura), nasal powder (Britannia Pharmaceuticals and Vernalis)) - Apomorphine Aspirair inhaler - Phase II - Apomorphine nasal powder - Phase III in EU - Other pipeline drugs (un-forecasted) - Excegran (AD-810N, zonisamide, Dainippon Pharmaceutical, pre-registration in Japan) - PD-02 - V1512 - Recent discontinuations Companies Mentioned: - Teva/Lundbeck - GlaxoSmithKline - UCB
For more information visit http://www.researchandmarkets.com/research/c84a4e/forecast_insight
Source: Datamonitor
Comments